FDA accepts Karyopharm's Xpovio combination application for myelofibrosis review
KPTI•The FDA accepted Karyopharm Therapeutics' supplemental application for XPOVIO with ruxolitinib to treat myelofibrosis and set a June 28, 2027, target action date.
KPTI•The FDA accepted Karyopharm Therapeutics' supplemental application for XPOVIO with ruxolitinib to treat myelofibrosis and set a June 28, 2027, target action date.
The FDA accepted Karyopharm Therapeutics' supplemental application for XPOVIO in combination with ruxolitinib to treat myelofibrosis. The agency set a June 28, 2027, target action date.